Patients with NSCLC have higher levels of compliance with immunotherapy protocols in the neoadjuvant setting than in the adjuvant setting.
Camu camu, containing castalagin, was safe in combination with immune checkpoint inhibitors for melanoma and NSCLC patients, with manageable adverse events. The melanoma cohort showed a 13% ORR in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback